文献速递基础与转化研究临床试验与 GCP

Ad26与MVA疫苗在急性治疗HIV感染者中的安全性和免疫原性及对治疗中断后病毒反弹的影响

Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.
PubMed 文献 · Nat Med · 2020-03-23

在26名急性HIV感染期间启动抗逆转录病毒治疗的个体中,给予含镶嵌HIV-1抗原的Ad26和改良安卡拉痘苗病毒载体或安慰剂。疫苗安全并产生强免疫应答,但相比安慰剂组仅将病毒反弹时间延迟数天,且未在治疗中断后实现病毒控制(临床试验NCT02919306)。

要点

  • Ad26/MVA镶嵌HIV疫苗在急性治疗HIV感染者中安全且免疫原性强。
  • 疫苗仅将治疗中断后病毒反弹时间较安慰剂延迟数天。
  • 未观察到治疗中断后的病毒血症控制。

核心结论

  • Ad26和MVA镶嵌HIV疫苗安全并诱导强免疫应答,但仅延迟病毒反弹数天且未实现病毒控制。

研究设计与样本

  • 探索性研究,在26名急性HIV感染期间启动抗逆转录病毒治疗的个体中给予Ad26和MVA载体疫苗或安慰剂。

主要发现

  • 疫苗安全并产生强免疫应答。
  • 相比安慰剂组,疫苗组病毒反弹时间仅延迟数天。
  • 治疗中断后未导致病毒血症控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Colby DJ, Sarnecki M, Barouch DH, et al. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nat Med. 2020. PMID: 32235883. doi:10.1038/s41591-020-0774-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。